Merck (MRK) will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL and its 4-valent HPV vaccine, GARDASIL from March 18-21
Importance
Level 1
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES